Volume 14 1987

Cancer Treatment Reviews

Editors
K. Hellmann and S. K. Carter

Academic Press
A Subsidiary of Harcourt Brace Jovanovich, Publishers
London San Diego New York
Boston Sydney Tokyo Toronto

215

Copyright © 1987 Academic Press Limited.

ALL RIGHTS RESERVED

No part of this volume may be reproduced in any form, by photostat, microfilm, or any other means, without written permission from the publishers.

Printed in Great Britain at Aberdeen University Press

Contents of Volume 14

No. 1, March 1987

Page

Greig, N. H., Optimizing drug delivery to brain tumors 1

Sørensen, J. B., Østerlind, K. and Hansen, H. H., Vinca alkaloids in the treatment of non-small cell lung cancer 29

Carr, I., Pettigrew, N. and Weinerman, B., Lymphatic metastasis and its treatment 53

Announcements 65

No. 2, June 1987

Shaw, I. C. and Graham, M. I., Mesna—a short review 67

Dykes, P. W., Bradwell, A. R., Chapman, C. E. and Vaughan, A. T. M., Radio-immunotherapy of cancer: clinical studies and limiting factors 87

Fentiman, I. S., Diagnosis and treatment of malignant pleural effusions . . 107

Ries, F., Sculier, J. P. and Klastersky, J., Diffuse bilateral pneumopathies in patients with cancer 119

Stalpers, L. J. A., Verbeek, L. M. and van Daal, W. A. J., Results of radiotherapy and surgery for glottic carcinoma 131

Willmott, N., Chemoembolisation in regional cancer chemotherapy: a rationale 143

Nos 3/4, December 1987

Hellmann, K., Hill, B. T. and Schmähl, D., Foreword 157

Arcamone, F., Clinically useful doxorubicin analogues 159

Israel, M., Seshadri, R. Koseki, Y., Sweatman, T. W. and Idriss, J. M., Amelioration of adriamycin toxicity through modification of drug-DNA binding properties 163

Takahashi, K., Ekimoto, H., Minamide, S., Nishikawa, K., Kuramochi, H., Motegi, A., Nakatani, T., Takita, T., Takeuchi, T. and Umezawa, H., Liblomycin, a new analogue of bleomycin 169

Carter, S. K., Improving the therapeutic index of systemic therapy with special emphasis on cisplatin and carboplatin 179

Hilgard, P., Current status of oxazaphosphorine analogue development . . 187

Page

Johnson, I. S., Spearman, M. E., Todd, G. C., Zimmerman, J. L. and Bumol, T. F., Monoclonal antibody drug conjugates for site-directed cancer chemotherapy: preclinical pharmacology and toxicology studies 193

Hill, B. T., *In vitro* screening of new drugs and analogues—specificity and selectivity 197

Barrett, A. J., Bone marrow transplantation 203

Price, L. A., Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity 215

Herman, E. H. and Ferrans, V. J., Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds 225

Scheulen, M. E., Reduction of pulmonary toxicity 231

Kemeny, and Daly J., Randomized study of intrahepatic (H) versus systemic (S) infusion of fluorodeoxyuridine (FUDR) in patients with liver metastases from colorectal carcinoma (CRC) (**abstract only**) 245

Friedl, P., Berger, M. R., Rozycki-Gerlach, W., Schlag, P. and Schmähl, D., Studies on experimental liver infusion and additional systemic detoxification 247

Westbury, G., Limb perfusion (**abstract only**) 257

Herrmann, R., Improvement of therapeutic index in gastrointestinal cancer . 259

Possinger, K., Wagner, H., Langecker, P. and Wilmanns, W., Treatment toxicity reduction: breast cancer 263

Engel, J., Schönenberger, H., Lux, F. and Hilgard, P., Estrophilic cisplatin derivatives 275

Eisenbrand, G., Berger, M., Fischer, J., Schneider, M., Zeller, W. and Tang, W., N′-(2-chloroethyl)-N′-nitrosocarbamoyl amino acid derivatives of steroid hormones 285

Stringfellow, D. A. and Schurig, J. E., The search for more active and less toxic mitomycin and etoposide analogs 291

Saletan, S., Mitoxantrone: an active, new antitumor agent with an improved therapeutic index 297

Unger, C., Nagel, G. A. and Eibl, H., Alkylphosphocholines: new agents with antineoplastic properties (**abstract only**) 305

Berger, M. R., Muschiol, C., Schmähl, D. and Eibl, H. J., New cytostatics with experimentally different toxic profiles 307

Seymour, L. W., Duncan, R., Kopečková, P. and Kopeček, J., Daunomycin- and adriamycin-*N*-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery 319

Page

Spittle, M. F., Significance of control of the side-effects of chemotherapy treatment 329

Stables, R., Andrews, P. L. R., Bailey, H. E., Costall, B., Gunning, S. J., Hawthorn, J., Naylor, R. J. and Tyers, M. B., Antiemetic properties of the $5HT_3$-receptor antagonist, GR38032F 333

Petru, E. and Schmähl, D., Second malignancies—risk reduction . . . 337

Macdonald, E. A., Cost-effectiveness of cancer chemotherapy: risks/benefit ratio—socio-economic and ethical considerations 345

Welch, D. R., Biologic considerations for drug targeting in cancer patients . . 351

Shaw, I. C., Mesna and oxazaphosphorine cancer chemotherapy 359

Kempf, S. R. and Ivankovic, S., Nephrotoxicity and carcinogenic risk of cis-platin (CDDP) prevented by sodium 2-mercaptoethane-sulfonate (Mesna): experimental results 365

Hellmann, K., Hutchinson, G. E. and Henry, K., Mitozantrone therapeutic index improvement by gangliosides 373

Buc-Calderon, P., Praet, M., Ruysschaert, J. M. and Roberfroid, M., Free radical modulation by *N*-substituted dehydroalanines, a new way to improve therapeutic activity of anticancer drugs 379

Sells, R. A., Gilmore, I. T., Owen, R. R., New, R. R. C. and Stringer, R. E., Reduction in doxorubicin toxicity following liposomal delivery 383

Aamdal, S., Fodstad, O. and Pihl, A. Some procedures to reduce *cis*-platinum toxicity reduce antitumour activity 389

Bagshawe, K. D., Radiochemotherapy with ^{125}I-5-iodo-2-deoxyuridine . . 397

Milford, Ward, A., The value of markers in fine tuning of chemotherapy . . 401

Johnson, I. S., Cullinan, G. J., Boder, G. B., Grindey, C. B. and Laguzza, B. C., Structural modifications of the vinca alkaloids 407

Pimm, M. V., Clegg, J. A., Caten, J. E., Ballantyne, K. D., Perkins, A. C., Garnett, M. C. and Baldwin, R. W., Biodistribution of methotrexate-monoclonal antibody conjugates and complexes: experimental and clinical studies 411

Announcements 421